Clinical Trials Browser

Phase 2/3 × Unknown × spartalizumab × Clear all

NCT05605613 2022-11-09

PD-1 Antibody in Addition to BACE in Patients With NSCLC: A Randomised Controlled Trial

Phase 2/3 Unknown

NSCLC

NCT03975036 2019-06-05

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Phase 2/3 Unknown

Other solid neoplasm

Advanced Solid Tumor